Alumni

Alumni
Providing technology platforms that can be tailored and applied to any disease treatable
Alumni
Agenovir is developing a novel class of nuclease-based anti-viral therapeutics for
Alumni
Amplyx Pharmaceuticals Inc is a preclinical stage company that re-engineers small molecule
Alumni
Using a novel new medicinal chemistry platform, HTI is focused on the development and
Alumni
Appili Therapeutics is dedicated to identifying, acquiring and advancing novel
Alumni
Assembly Biosciences is an infectious disease-focused biopharmaceutical company developing
Alumni
Cidara Therapeutics is applying its small molecule immunotherapy platform to treat life
Alumni
The Cell Culture Engineering Lab of the Federal University of Rio de Janeiro, suported by
Alumni
IGXBio is developing advanced DNA immunotherapies for diseases- our lead program, GenePro,
Alumni
Inflammatix is developing host-response-based diagnostics that ‘read’ the immune system.
Alumni
ViraCyte is a clinical stage biopharmaceutical company focused on discovering and